Abstract
To better focus on core businesses such as fluorinated chemicals and titanium dioxide, Chemours has agreed to sell its glycolic acid business to the private equity firm Iron Path Capital for $137 million. While the company doesn’t break out sales for glycolic acid specifically, the business segment that houses the glycolic acid unit generated revenues of $116 million in 2022. Iron Path has founded the firm PureTech Scientific to run the business. Separately, Chemours has seen three top executives depart in the past 3 months. Chief Financial Officer Sameer Ralhan is leaving the company June 19; he is being replaced by Jonathan Lock, senior vice president and chief development officer, who joined Chemours in 2018. Alisha Bellezza, president of thermal and specialized solutions, resigned in May. And Edwin Sparks, president of titanium technologies and chemical solutions, left the firm at the end of March to lead W. R. Grace. Chemours
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
